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Abstract
Intraductal carcinoma of the prostate gland (IDCP), which is now categorised as a distinct entity by WHO 2016, includes two
biologically distinct diseases. IDCP associated with invasive carcinoma (IDCP-inv) generally represents a growth pattern of
invasive prostatic adenocarcinoma while the rarely encountered pure IDCP is a precursor of prostate cancer. This review
highlights issues that require further discussion and clarification. The diagnostic criterion Bnuclear size at least 6 times normal^
is ambiguous as Bsize^ could refer to either nuclear area or diameter. If area, then this criterion could be re-defined as nuclear
diameter at least three times normal as it is difficult to visually compare area of nuclei. It is also unclear whether IDCP could also
include tumours with ductal morphology. There is no consensus whether pure IDCP in needle biopsies should be managed with
re-biopsy or radical therapy. A pragmatic approach would be to recommend radical therapy only for extensive pure IDCP that is
morphologically unequivocal for high-grade prostate cancer. Active surveillance is not appropriate when low-grade invasive
cancer is associated with IDCP, as such patients usually have unsampled high-grade prostatic adenocarcinoma. It is generally
recommended that IDCP component of IDCP-inv should be included in tumour extent but not grade. However, there are good
arguments in favour of grading IDCP associated with invasive cancer. All historical as well as contemporary Gleason outcome
data are based on morphology and would have included an associated IDCP component in the tumour grade. WHO 2016
recommends that IDCP should not be graded, but it is unclear whether this applies to both pure IDCP and IDCP-inv.
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Introduction
Intraductal carcinoma of the prostate gland (IDCP) is
characterised by a lumen-spanning proliferation of atypical
prostatic epithelium within expanded pre-existing prostatic
ducts, with, at least, a partially preserved basal cell layer.
The earliest description of IDCP, to our knowledge, was in-
cluded in a systematic autopsy study published in 1938 by EP
Gaynor [1]. It was, however, not until 1985 that IDCP was
described as a distinct entity by Kovi et al. [2]. In this study,
they demonstrated IDCP in 48% of 139 adenocarcinomas of
the prostate in a series consisting mainly of transurethral re-
section (TUR) specimens. McNeal et al. provided a more de-
tailed description of IDCP in 1986 and established its associ-
ation with aggressive prostate cancer [3] and in 1996 de-
scribed the key morphological criteria for the diagnosis of
IDCP [4]. Guo and Epstein [5] refined these criteria to identify
IDCP in needle biopsies and their criteria are currently those
most frequently used to identify IDCP in all types of prostate
specimens. IDCP was formalised as a biologically distinct
entity in the 2016 edition of the World Health Organization
(WHO) Classification of Tumours of the Prostate Gland [6].
In the past decade, there has been considerable interest in
IDCP and several reviews of this entity have been published
[7–10]. However, there are some significant issues relating to
the diagnosis and reporting of IDCP that merit more detailed
discussion. In this review, we focus on these more controversial
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issues, highlight areas that require further discussion and suggest
some potential solutions.
Nature of IDCP
Until recently, IDCP was an issue largely discussed by aca-
demic uropathologists. However, with the increasing aware-
ness and reporting of this entity by practicing pathologists,
there is a greater potential for misunderstanding its nature.
Since the publication of the seminal study of Kovi et al. [2],
IDCP was considered to represent a growth pattern of invasive
prostatic adenocarcinoma showing aggressive infiltration and
expansion of pre-existing benign prostatic ducts (IDCP-inv).
However, in 2010, Robinson and Epstein studied 21 specimens
from radical prostatectomies following a diagnosis of pure IDCP
in needle biopsies and described two cases in which the
completely submitted prostate gland showed only IDCP with
no co-existing component of invasive carcinoma identified
[11]. Similarly, in 14 (2%) of 901 radical prostatectomy speci-
mens studied by Miyai et al., IDCP was found to be spatially
separate from invasive carcinoma and interpreted as Bprecursor-
like IDCP^ [12]. Thus, while IDCP generally represents a
growth pattern of invasive prostatic adenocarcinoma, it may oc-
casionally represent a precursor of prostatic adenocarcinoma. It
is important to appreciate that the morphological entity BIDCP^
includes two biologically distinct diseases, as this has significant
implications for its diagnosis and reporting.
In prostate needle biopsies, IDCP is usually associated with
an overtly invasive component of prostate carcinoma. The less
common scenario where it is unaccompanied by invasive can-
cer has been referred to as pure or isolated IDCP. However,
most instances of pure IDCP in prostate needle biopsy repre-
sent IDCP-inv with an unsampled invasive component.
Some pathologists and clinicians confuse IDCPwith ductal
carcinoma of the prostate. The term ductal in IDCP refers to
the location of the tumour within large ducts, while ductal in
ductal adenocarcinoma refers to the tumour cell phenotype, as
ductal tumours are defined by their distinctive cytology.
It is unclear whether the term IDCP should be restricted to
tumours showing an acinar phenotype or could also include
tumours with ductal morphology. Papillary tumours with a
prostatic ductal cellular morphology may have preserved bas-
al cells, and such tumours have been variably classified as
ductal adenocarcinoma, non-invasive ductal adenocarcinoma
or IDCP [13–15]. In a recent survey of European pathologists,
39% of respondents noted that they would use the term IDCP
only for acinar proliferations, while 58% would include tu-
mours with ductal morphology (Unpublished Observation).
This issuewould be particularly important if IDCP is managed
by re-biopsy rather than radical therapy. The terminology for
non-invasive tumours of ductal phenotype needs to be
standardised.
Diagnosis of IDCP
The diagnosis of IDCP is generally made using the morpho-
logical criteria described by Guo and Epstein, which were
recommended by the WHO in 2016 [5, 6]. It must be appre-
ciated that Guo and Epstein set out criteria to identify pure
IDCP in prostate needle biopsies, which would then be man-
aged with radical therapy, even in the absence of a co-existing
invasive component. Hence, these criteria were designed to
include only cases in which the possibility of high-grade pros-
tatic intraepithelial neoplasia (HGPIN) could be definitively
excluded. The bar was therefore set very high as this definition
of IDCP would exclude cases of IDCP in which the morphol-
ogy overlaps with that of HGPIN.
It has recently been proposed that the spectrum of IDCP
should be expanded by designating some atypical intraductal
proliferations, which fall short morphologically of Bclassical^
IDCP according to Guo and Epstein criteria, as low-grade
IDCP (LGIDCP) [16]. Further, it has been recommended that
this particularly applies if on immunostaining the tumours are
ERG positive and PTEN negative, which is the typical
immunoprofile of IDCP. These authors suggest that such pro-
liferations should be managed by prompt re-biopsy rather than
the radical therapy recommended by some experts for classi-
cal IDCP. Given the current state of uncertainty regarding the
diagnosis and management of IDCP, the introduction of a new
category of LGIDCP could cause significant confusion among
pathologists and clinicians. Moreover, expansion of the spec-
trum of IDCP risks over-treatment with the potential for rad-
ical therapy for patients with low grade disease [17].We prefer
the more descriptive term Batypical proliferation suspicious
for intraductal carcinoma^ (ASID) for glandular proliferations
that are morphologically indeterminate between HGPIN and
IDCP [18]. Unlike LGIDCP, ASID should not be considered a
diagnostic entity but merely an indication of diagnostic uncer-
tainty analogous to ASAP (atypical small acinar proliferation)
and PINATYP (HGPIN associated with atypical small acini
suspicious for invasive cancer).
The reporting of ASID/LGIDCP morphology may be par-
ticularly important when encountered in association with low-
grade invasive carcinoma as this could have management im-
plications as detailed below.
Recent studies have shown significant inter-observer vari-
ation in the diagnosis of IDCP. Iczkowski et al. circulated
photomicrographs to 39 uropathologists and reported only
43% agreement with the original diagnosis of IDCP [19].
Varma et al. surveyed 23 expert uropathologists and found
significant variation in the diagnostic criteria and rules used
to report IDCP [20]. With more widespread recognition of
IDCP, through its acceptance as a novel entity by the WHO
[6], there is a danger of an even greater degree of confusion
and variation in the diagnosis and reporting of IDCP among
non-specialist pathologists.
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While the apparent lack of inter-observer reproducibility in
the diagnosis of IDCP may be due to the inevitable variation
in the interpretation of borderline morphology, it may also be
due to an entirely avoidable variation in the interpretation of
the definitions of diagnostic criteria. In view of this, diagnostic
criteria for IDCP should be unambiguous to ensure consistent
diagnosis and reporting.
Guo and Epstein proposed that solid and dense cribriform
growth patterns are diagnostic of IDCP, while a diagnosis of
IDCP would be rendered in loose cribriform and
micropapillary proliferations only if there was marked nuclear
enlargement or non-focal comedonecrosis. It is now clear that
the definitions of Bmarked nuclear enlargement^ and Bdense^
cribriform proliferation need further clarification.
Marked nuclear enlargement has been defined as a Bnuclear
size at least six times normal^, which has been has been var-
iably interpreted as Bsize^ may apply to nuclear diameter,
radius or area. In a recent survey, 74% of expert
uropathologists defined size by nuclear area and 21% by nu-
clear diameter [20]. A six times increase in nuclear diameter
would be equivalent to a 36× increase in nuclear area, which
would be very rarely encountered in clinical practice (Fig. 1).
The nuclear size criterion was proposed byGuo and Epstein to
improve reproducibility in the diagnosis of IDCP in the ab-
sence of solid growth pattern, dense cribriform growth pattern
or comedonecrosis. However, inconsistent interpretation of
this definition could lead to marked variation as some pathol-
ogists would require marked nuclear enlargement (greater
than six times normal area) while others would require bizarre
nuclei (greater than six times normal diameter). Defining size
based on nuclear area would be problematic in routine practice
as it is difficult to visually compare the area of nuclei. Hence,
if this interpretation of nuclear size criterion is appropriate,
then it could be re-defined as nuclear diameter at least three
times normal (approximately equivalent to a nuclear area of at
least six times normal) to avoid ambiguity. Moreover, since
normal prostatic secretory cell nuclei can vary significantly,
nuclear size could be defined in relation to that of lymphocytes
or red blood cells.
The nuclear enlargement cut-off is arbitrary as there were
no studies comparing outcome of various nuclear sizes so a
visual estimate of nuclear size is sufficient. It may even be
appropriate to redefine this criterion more simply as Bsevere
nuclear enlargement^ with publication of microphotographs
to illustrate the minimum degree of nuclear enlargement re-
quired for a diagnosis of IDCP in this setting.
The dense cribriform pattern criterion was originally de-
fined as foci in which Bsolid areas predominated over luminal
spaces^, which would logically be interpreted as indicating
proliferations that would consist of > 50% epithelium [5].
However, in a recent review paper, Wobker and Epstein re-
defined dense cribriform pattern as B>70% epithelium as op-
posed to lumens^ [9]. This raising of the bar for diagnosis of
IDCP is prudent as it would reduce the risk of over-diagnosis
of IDCP. This change does, however, need to be sufficiently
emphasised to ensure that it does not lead to further variation
in the diagnosis of IDCP, due to the existence of conflicting
criteria.
BNon-focal comedonecrosis^ is another criterion described
for the diagnosis of IDCP in foci lacking solid or dense crib-
riform growth patterns [5]. However, true focality of
comedonecrosis can be difficult to establish due to the intrin-
sic sampling error of needle biopsies. Comedonecrosis can be
distinguished from intraluminal secretions by the presence of
nuclear material and ragged luminal surface due to cellular
necrosis. Most foci of morphologically comedonecrosis
Gleason pattern 5 prostate cancer probably represent IDCP
as discussed in the section on grading issues.
Differential diagnosis
Although diagnostic criteria for IDCP were primarily de-
signed to distinguish IDCP from HGPIN, the other major
and difficult differential diagnosis is invasive prostate cancer.
The accurate distinction of cribriform/comedonecrosis pat-
terns of IDCP from cribriform/comedonecrosis invasive pros-
tate cancer is often not possible without the aid of basal cell
marker immunohistochemistry (Fig. 2). Hence, some studies
analyse IDCP and invasive cancer with cribriform pattern to-
gether [21]. Basal cell marker immunoreactivity is often
patchy in IDCP and as a consequence, even immunohisto-
chemistry may not be conclusive in differentiating IDCP from
invasive cancer. While the identification of basal cells would
support a diagnosis of IDCP, the absence of basal cell marker
immunoreactivity does not exclude the possibility of the
Fig. 1 This case could meet B> six times normal^ nuclear size criterion
for intraductal carcinoma of the prostate if size is defined as nuclear area
but not if defined as nuclear diameter (blue dot: size of normal nucleus,
green dot: size six times normal area and red dot: size six times normal
diameter)
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suspect glands representing IDCP with absence of basal cells
in the examined plane of section (Fig. 3). Other differential
diagnoses include clear cell cribriform hyperplasia, ductal
adenocarcinoma, PIN-like ductal carcinoma and urothelial
carcinoma and the differentiating features of these lesions
these have been extensively covered in recent reviews [7–10].
Fig. 3 Intraductal carcinoma of the prostate with very patchy basal cells identified by immunohistochemistry. At least some of the glands lacking basal
cell immunoreactivity represent intraductal rather than invasive carcinoma (a haematoxylin and eosin, b CK 5/6)
Fig. 2 Intraductal carcinoma of the prostate with an infiltrative growth pattern may bemorphologically difficult to distinguish from invasive cancer. One
focus shows comedonecrosis morphologically suggesting Gleason pattern 5 invasive carcinoma (a haematoxylin and eosin, b CK5/6)
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Molecular pathology
Early studies on IDCP focussed on features such as prolifera-
tion or loss of heterozygosity (LOH) of common tumour sup-
pressor genes. Cohen et al. analysed Ki-67 fractions in IDCP
and described proliferation rates that were comparable to ad-
jacent invasive carcinoma [22]. In a further study of this group
analysing a set of 12 loci commonly altered in prostate cancer,
LOH was found in 60% of IDCP [23]. In comparison,
Gleason pattern 3 carcinoma showed no LOH, whereas
Gleason pattern 4 tumours had 29% of LOH, indicating that
IDCP might be even more disturbed that invasive carcinoma.
Bettendorf et al. used PCR to demonstrate particularly high
rates of LOH in PTEN (45%), TP53 (60%) and RB (81%)
[24]. However, these studies were conducted before the pub-
lication of the WHO 2016 definition of IDCP and hence the
applied definitions of IDCP may vary.
The prevalence of ETS gene rearrangements in high grade
PIN, invasive and intraductal carcinoma was analysed by Han
et al., and they found that HGPIN in their cohort lacked ERG
gene rearrangement, whereas it was present in 75% of IDCP,
matching the positivity of adjacent invasive glands [25]. This
was confirmed by Lotan et al. who studied immunohisto-
chemical PTEN expression in prostatic tissues and proposed
cytoplasmic PTEN loss as a helpful diagnostic criterion for the
molecular separation of HGPIN (100% PTEN positive) from
IDCP (only 16% PTEN positivity) [26]. Schneider and
Osunkoya demonstrated that ERG immunoreactivity was
comparable in ERG positive IDCP cases and adjacent inva-
sive adjacent carcinoma, endorsing the assumption that
intraductal carcinoma of the prostate probably represents col-
onization of benign glands by adjacent pre-existing conven-
tional prostatic adenocarcinoma [27]. A detailed analysis of
ERG and PTEN in HGPIN, invasive carcinoma and IDCP by
Haffner et al. provided further evidence that invasive adeno-
carcinoma can morphologically mimic HGPIN through retro-
grade colonization of benign glands [28]. More recently,
Tolkach et al. proposed a re-think of our definitions and con-
cepts of BHGPIN^ that is spatially associated with invasive
carcinoma, as this may represent a post-invasive re-entry le-
sion and not, as assumed so far, a precursor lesion [29].
Atypical intraductal cribriform proliferations (AIP) that fall
short of the criteria of IDCP were examined by Hickman
et al., who found similar ERG and PTEN expression patterns
in AIP and IDCP, which, as they suggest, might imply a sim-
ilar clinical relevance [30].
Apart from PTEN and ERG, no other molecular markers
are, as yet, established as diagnostic markers of IDCP. IDCP
has been associated with BRCA2 defects in familial prostate
cancer, as it was shown that intraductal growth was signifi-
cantly more prevalent in xenografts from BRCA2-mutated
cases than in sporadic cases [31]. However, a comparison of
Gleason score matched primary cases of familial vs. sporadic
cases is to our knowledge still lacking. Lindberg et al. con-
ducted a detailed comparison of copy-number variations
(CNV) in nodal metastasis of a case of prostate cancer with
those in 34 different foci of the corresponding primary tumour
[32]. Surprisingly, the closest molecular semblance to lymph
node metastasis was found in the focus of IDCP. As a purely
intraductal process would be unable to metastasise, it is likely
that a corresponding invasive focus was not sampled for the
CNV analysis. However, these findings are consistent with
intraductal growth being a hallmark of more aggressive tu-
mours and or even that the intraductal component of a tumour
is enriched for tumour cells with a particularly aggressive
behaviour. The role of the inevitable intraductal hypoxia that
might promote further tumour progression in IDCP has not yet
been clarified, even though hypoxia has long been recognised
as an accelerator of tumour dedifferentiation and progression
[33, 34]. The general association of IDCP, genomic instability
and hypoxia was recently analysed in an impressive multicen-
ter study that also confirmed the prognostic value of IDCP or
glands with cribriform growth (CA+) [35]. Furthermore, they
demonstrated that IDCP/CA+ prostate cancers had increased
hypoxic tumour subpopulations when compared with
IDCP/CA– prostate cancers and that they also exhibited in-
creased percentages of genomic alterations. Finally, they
found the long non coding RNA SChLAP1 at threefold higher
levels in IDCP/CA+ cases, which warrants further study to
clarify its biological or even diagnostic role. The association
of IDCP/CA+ with genomic instability was also confirmed in
a clever re-analysis of publically available TCGA data, which
also showed higher rates of point mutations in TP53, SPOP
and FOXA1 in these cases [36].
Frequency of IDCP
The reported incidence of IDCP in needle biopsies and radical
prostatectomy specimens varies widely depending on the patient
cohort studied, as IDCP is more commonly seen in association
with high-grade, high-stage invasive prostate cancer. In one
large series, Watts et al. found IDCP in 2.8% of 1176 consecu-
tive prostate biopsies, including pure IDCP in 0.26% [37].
The three proven cases of pure IDCP without an associated
invasive tumour component in the prostate gland were in rad-
ical prostatectomy specimens from series where radical ther-
apy was offered to patients identified as having pure IDCP in
needle biopsies [11, 38]. The true incidence of pure IDCP is
unknown although the comprehensive examination of
cystoprostatectomy specimens could provide useful informa-
tion. These specimens were used in the study of Siadat et al.
reported in 2015 [39]; however, they analysed only specimens
with, at least, Gleason score 7 tumours, while there was only
partial sampling of the specimens submitted for histological
examination in the series examined by Morais et al. [40].
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Before rendering a diagnosis of pure IDCP in a needle
biopsy set, a diligent search for invasive carcinoma is re-
quired. If pure IDCP is suspected, the examination of deeper
levels must be considered in order to determine the potential
presence of an albeit limited component of invasive tumour.
Clinical significance
Several studies have demonstrated the clinical significance of
IDCP, both in needle biopsies and in radical prostatectomy
specimens.
The presence of an IDCP component within a prostate
cancer diagnosed on needle biopsy has been shown to corre-
late with increased risk of tumour recurrence and reduced
survival [41]. IDCP in radical prostatectomy specimens has
also been correlated with high-stage disease and shown to be a
predictor of post-surgical biochemical recurrence [42].
IDCP-inv in needle biopsies is generally associated with ex-
tensive high-grade prostate cancer in the same specimen, as well
as in the corresponding radical prostatectomy [7–10]. In view of
this, it is not surprising that some studies have suggested that
IDCP-inv is associated with an increased rate of biochemical
recurrence and metastasis after radiotherapy, as well as resis-
tance to androgen suppression and chemotherapy [43].
Occasionally, IDCP-inv in a needle biopsy may be associat-
ed with low-grade invasive prostate cancer. Khani and Epstein
described the outcome of 62 patients in whom the needle biop-
sy showed IDCP and Gleason score 3 + 3 = 6 adenocarcinoma
[44]. Six percent of these men had metastatic disease at presen-
tation. Of the 45 men who received radical therapy, 20% devel-
oped disease progression within 3 years, 13% ultimately devel-
oped metastatic disease and 7% died of disease. Thus, the clin-
ical and pathological outcomes of Gleason score 3 + 3 = 6 in-
vasive cancer associated with an IDCP component in biopsies
are clearly very different from that of usual Gleason score 3 +
3 = 6 prostate cancer without associated IDCP.
Pure IDCP in needle biopsies generally represents IDCP-
inv with an unsampled invasive component, and its distinction
from HGPIN is particularly important in contemporary prac-
tice, as current guidelines do not recommend routine re-biopsy
for the latter, particularly when focal.
Management implications
The management of patients with pure IDCP in needle biop-
sies is controversial. Some experts recommend radical therapy
even in the absence of an associated invasive component as
such patients often have high-grade, locally advanced or met-
astatic prostatic cancer [5, 15]. On the contrary, other experts
favour re-biopsy as some patients may have only pure IDCP
in the subsequent radical prostatectomy specimen [45].
Men with pure IDCP should, at least, undergo prompt
multiparametric MRI examination and re-biopsy. Due to the
association between IDCP and high-volume invasive prostate
cancer, re-biopsy is likely to be positive. If; however, the re-
biopsy shows no invasive malignancy, then there is uncertainty
as to how the patient should be managed. Unlike low volume
Gleason 3 + 3 = 6 invasive prostate cancer, delay in the com-
mencement of therapy following a diagnosis of pure IDCP in a
needle biopsy could have serious consequences if there is occult
high-grade cancer elsewhere in the prostate gland.
A pragmatic approach would be to recommend radical
therapy for extensive pure IDCP that is morphologically un-
equivocal for high-grade prostate cancer and re-biopsy for
IDCP with features that are morphologically equivocal for
invasive carcinoma [8]. Adoption of such a strategy could
reduce overuse of immunohistochemistry to exclude the pos-
sibility of IDCP in cases where the morphology is of high-
grade invasive cancer (Figs. 2 and 3).
In contrast to the controversy surrounding themanagement of
pure IDCP, there is general consensus that active surveillance is
not an appropriate option when low-grade invasive cancer is
associatedwith IDCP, as such patients generally have unsampled
high-grade prostatic malignancy [44]. This scenario, however, is
rare, and there is a need for further studies to determine whether
active surveillance could be considered for men with negative
MRI and only focal IDCP associated with low-grade invasive
cancer. Similarly, it is unclear whether men on an active surveil-
lance program with stable PSA levels and radiological findings
should have radical therapy, if a routine re-biopsy shows focal
IDCP associated with low-grade invasive cancer.
Another clinical dilemma would be low-grade invasive car-
cinoma associated with LGIDCP/ASID. This is particularly so
when the latter has the morphology of cribriform (Gleason pat-
tern 4) invasive carcinoma with basal cells identified on immu-
nohistochemical staining, but lacking the dense cribriform ar-
chitecture, marked pleomorphism or comedonecrosis, which
would warrant a diagnosis of IDCP (Fig. 4). It is generally
recognised that cribriform invasive carcinoma cannot be reli-
ably distinguished from cribriform IDCP without immunohis-
tochemistry (Figs. 2 and 3), and several studies suggest that the
prognostic significance of cribriform carcinoma diagnosed by
morphology alone is similar to that of IDCP [21, 45, 46].
Hence, radical therapy should be considered for low-grade in-
vasive carcinoma associated with LGIDCP/ASID with mor-
phology of cribriform (Gleason pattern 4) invasive carcinoma.
Reporting of IDCP
Tumour extent
Most experts recommend that an associated IDCP component
be included when assessing tumour extent in biopsies with
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invasive prostate cancer [8, 20]. Arguments in favour of in-
cluding IDCP in assessment of tumour extent include the dif-
ficulty in distinguishing IDCP and invasive components, the
adverse prognostic significance of IDCP and that in most
cases, this represents invasive carcinoma extending into be-
nign ducts. A counter argument is that IDCP is not actually
invasive in prostatic stroma and hence more comparable with
vascular invasion, which is not included in tumour size esti-
mation in other sites. We recommend that it must be clearly
indicated in the report if the reported tumour extent has been
significantly influenced by the presence of IDCP.
Tumour grade
The appropriateness of Gleason grading of IDCP, particularly
in biopsy material, is controversial. The International Society
of Urological Pathologists (ISUP) consensus conference on
prostate cancer grading, held in 2014, recommended that
Fig. 4 ISUP grade 1 invasive cancer associated with a loose cribriform
proliferation, which is morphologically Gleason pattern 4 but shows a
prominent basal cell layer and is ERG positive and PTEN negative.
However, the cribriform proliferation lacks marked nuclear atypia or
comedonecrosis to warrant a diagnosis of intraductal carcinoma and is
interpreted as atypical proliferation suspicious for intraductal carcinoma
(ASID) (a haematoxylin and eosin, b CK5/6, c ERG, d PTEN)
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IDCP should not be graded and this was subsequently en-
dorsed by the WHO in 2016 [6, 47].
As discussed earlier, IDCP includes two biologically dis-
tinct diseases that need to be considered separately. Pure IDCP
is a precursor lesion analogous to HGPIN, while IDCP-inv
generally represents a growth pattern of aggressive invasive
carcinoma. Thus, having a single rule for reporting, all IDCP
would be akin to uniform reporting guidelines for HGPIN and
invasive carcinoma. This clearly would be inappropriate as
HGPIN is not graded, while it is standard practice to report
the Gleason score in most cases of invasive prostate cancer.
Unfortunately, grading based upon these two scenarios (pure
IDCP and IDCP-inv) was not separately discussed at the 2014
ISUP consensus conference and is not mentioned in the 2014
ISUP grading classification for prostate cancer [47].
The main argument against grading IDCP is that tumour
grading is designed and validated only for invasive carcinoma,
while IDCP may represent a precursor lesion. Although most
cases of pure IDCP in prostate needle biopsies represent
IDCP-inv with an unsampled invasive component, it would
be prudent not to grade pure IDCP as some cases appear to
represent an aggressive precursor lesion rather than invasive
prostate cancer. Moreover, there is no consensus regarding the
appropriateness of radical therapy for pure IDCP and
reporting a Gleason score in such cases may lead to urologists
interpreting and treating it as invasive cancer. However,
Gleason grading of IDCP-inv does merit more detailed dis-
cussion as there are several arguments in favour of including
the IDCP component when grading IDCP-inv [48].
An IDCP component in IDCP-inv almost always repre-
sents a growth pattern of aggressive invasive carcinoma rather
than an associated precursor lesion. Hence, one would gener-
ally be grading invasive tumour if this component is included
in the Gleason score. The strongest argument favouring inclu-
sion of IDCP component in Gleason score is that all historical
as well as contemporary Gleason outcome data are based on
morphology and would have included an associated IDCP
component in the tumour grade. We are unaware of any evi-
dence regarding the outcome of Gleason grading based on
sections where the presence of basal cells was assessed by
immunohistochemistry and there are several precedents for
pathology reporting based on morphological rather than im-
munohistochemical results. For example, prostatic small cell
neuroendocrine carcinoma is primarily a morphological diag-
nosis as such tumours may occasionally be negative for all
neuroendocrine markers, which conversely may be expressed
by usual prostatic acinar adenocarcinoma.
The Gleason grading system was developed prior to the
introduction of immunohistochemistry, and it is recognised that
many foci of comedonecrosis pattern of Gleason pattern 5 in-
vasive carcinoma have an at least partially preserved basal layer
and would represent IDCP. Recently, Fine et al. demonstrated
the presence of a basal cell layer in at least some
comedonecrosis pattern 5 in 18 (95%) of 19 cases with 12
(63%) cases showing basal cell marker immunoreactivity in
all foci of comedonecrosis [49]. They recommend careful eval-
uation of the duct/acinar periphery of comedonecrosis foci to
detect basal cells, mandatory use of immunohistochemistry in
such cases if basal cells are not evident on H&E examination
and reconsideration of routine grading of comedonecrosis as
pattern 5. However, all these cases were identified in the setting
of high-grade high-volume prostate cancer and comedonecrosis
IDCP cannot be reliably distinguished from invasive carcinoma
by H&E or basal cell immunohistochemistry. Flattened tumour
cells and fibroblasts may be morphologically indistinguishable
from basal cells while some foci interpreted as invasive carci-
noma following immunohistochemistry are likely to represent
IDCP in which the patchy basal cells were absent in the immu-
nostained plane of section. In the absence of evidence that the
biological outcome of comedonecrosis IDCP is different from
that of comedonecrosis invasive prostate cancer, it would be
simpler and more reproducible to continue reporting
comedonecrosis foci as pattern 5 prostate cancer without
resorting to immunohistochemistry.
There is general agreement that IDCP is a risk factor for
aggressive cancer, but the presence of IDCP is not included in
commonly used prognostic nomograms, which means that
there is a danger of the feature being ignored by the urologists.
In the report by Khani and Epstein, 11 (18%) of 62 patients
with Gleason score 3 + 3 = 6 with IDCP were placed on active
surveillance despite the reports noting the association of IDCP
with high-grade aggressive disease and 6 (55%) of them sub-
sequently developed disease progression [44]. Moreover,
there is no scope for including a text comment on the presence
of IDCPwhen incorporating Gleason scores into databases for
research and epidemiological purposes.
Khani and Epstein recommend that IDCP-inv identified in
biopsy/TURP specimens should be reported separately as
three (19%) of their 16 patients, with IDCP and Gleason score
3 + 3 = 6 as the highest grade on biopsy, had only Gleason
score 3 + 3 = 6 cancer in their radical prostatectomy speci-
mens [44]. It should be emphasised, however, that all three
of these prostatectomy specimens were only partially submit-
ted for histological examination so the possibility of
unsampled high-grade tumour cannot be excluded.
Moreover, one of these patients subsequently developed bio-
chemical recurrence while another was stage pT3a on radical
prostatectomy, suggesting that at least two of the three patients
had clinically significant tumours.
WHO 2016 recommends that IDCP should not be graded,
but it is unclear whether this applies to both pure IDCP and
IDCP-inv [6]. SinceWHO 2016 recommends the use of an in-
situ behaviour code (/2) for IDCP, it can be argued that the
recommendation is applicable only to pure IDCP. This is an
issue that needs to be clarified in future editions of the WHO
classification and guidelines.
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